11
May
2022
The Limits of Biomedical Innovation, and Why We Should Embrace Them
Last October, I wrote for this publication about the emergence of Antibody-Drug Conjugates (ADCs) for cancer, based on my father’s experience being treated with Padcev for bladder cancer. A few months later, I posted on Twitter that, while Padcev had stopped working for my father, he had since started on another ADC called Trodelvy. His tumors had shrunk. He was... Read More